Maintenance strategies after anti-EGFR-based induction in metastatic colorectal cancer: A systematic review and bayesian network meta-analysis

Mastrantoni, Luca; Beccia, Viria; Caira, Giulia; Trovato, Giovanni; Calegari, Maria Alessandra; Basso, Michele; Salvatore, Lisa; Pozzo, Carmelo; Tortora, Giampaolo; Bria, Emilio; Orlandi, Armando

doi:10.1016/j.critrevonc.2023.104106

Cited by 2 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In terms of intervention, the study by Kong et al did not explore the impact of panitumumab on patients with potentially resectable mCRC, and there are some differences in retrieval strategies and data processing between present study and those of Kong et al, so the results need further confirmation [ 47 ]. As far as the participants in the study are concerned, participants in Li et al, Wu et al, and Mastrantoni et al were mCRC patients [ 48 , 49 ] and did not limit participants to patients with potentially resectable mCRC. Present study limited the participants to patients with potentially resectable mCRC and conducted a systematic search of four major databases and rigorous data analysis, ultimately including only data from RCT for analysis so that more targeted research can be conducted on these patients.…”

Section: Discussionmentioning

confidence: 99%

The efficacy and safety of anti-EGFR target agents in patients with potentially resectable metastatic colorectal cancer: a meta-analysis of randomized controlled trials

Wang,

Li,

Huang

et al. 2023

World J Surg Onc

View full text Add to dashboard Cite

Background Adding anti-epidermal growth factor receptor (anti-EGFR) target agents to conversion therapy may improve the resection rates and survival of patients with potentially resectable metastatic colorectal cancer (mCRC). This study aims to analyze the efficacy and safety of additional anti-EGFR target agents. Methods A systematic search was conducted on PubMed, Web of Science, Embase, and Cochrane Library. And all relevant studies published in English before January 2023 were collected to explore the impact of additional anti-EGFR targeted agent on the efficacy and safety of patients with potentially resectable mCRC (PROSPERO: CRD42022340523, https://www.crd.york.ac.uk/PROSPERO/). Results This study included a total of 8 articles, including 2618 patients. The overall response rate (ORR) and R0 resection rates of the experimental group were higher than those of the control group, while there was no significant difference in progression-free survival (PFS) and overall survival (OS) between the two groups. In RAS/KRAS wild-type patients, the ORR (RR: 1.20, 95% Cl: 1.02–1.41, p = 0.03), R0 resection rate (RR: 1.60, 95% Cl: 1.17–2.20, p = 0.003), PFS (HR: 0.80, 95% Cl: 0.68–0.93, p = 0.003), and OS (HR: 0.87, 95% Cl: 0.76–0.99, p = 0.031) of the experimental group were higher than those of the control group. While in KRAS mutant patients, there was no statistical difference between the two groups in ORR, R0 resection rate, PFS, and OS. Conclusion The addition of anti-EGFR targeted agents can improve the prognosis of RAS/KRAS wild-type patients with potentially resectable mCRC, while KRAS mutant patients may not benefit. In addition, the overall safety factor was controllable.

show abstract

Section: Discussionmentioning

confidence: 99%